eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | chronic myeloproliferative disease |
| Comorbidity | C0040053|thrombosis |
| Sentences | 20 |
| PubMedID- 21122317 | [correlative study between jak2 mutation and thrombosis in patients with myeloproliferative neoplasm.] |
| PubMedID- 22701830 | Hepatic vein thrombosis may be associated with myeloproliferative disease, sepsis, dehydration, polycythemia vera, pregnancy, and hepatocellular carcinoma. |
| PubMedID- 25339837 | Therapeutic options for gastric variceal bleeding in the presence of extensive portal vein thrombosis associated with a myeloproliferative disorder are limited. |
| PubMedID- 21986846 | How to manage thrombosis in myeloproliferative neoplasms. |
| PubMedID- 25878908 | There are contradictory reports about the association between jak2 mutation and thrombosis in patients with myeloproliferative neoplasm. |
| PubMedID- 25970015 | Risk of thrombosis in patients with myeloproliferative neoplasms and elevated platelet counts. |
| PubMedID- 21505581 | These explain thrombophilia and increased risk of thrombosis in patients with chronic myeloproliferative disorders, particularly those with jak2 mutation present. |
| PubMedID- 26345555 | myeloproliferative neoplasms are frequently complicated by thrombosis and bleeding. |
| PubMedID- 25191727 | Clinical risk factors of thrombosis in patients with ph-negative myeloproliferative neoplasms, who had experienced radiation exposure due to the chornobyl accident. |
| PubMedID- 24084459 | Aim: the aim of this study was to examine the jak2 v617f, the g1691a allele of factor v, and the g20210a prothrombin gene mutation status, and their predictive value for thrombosis in patients with ph-negative myeloproliferative neoplasms (mpn) in ukraine, with special emphasize to patient exposed to ionizing radiation due to the chernobyl accident. |
| PubMedID- 23031663 | It is unclear whether the somatic jak2v617f mutation, a marker for chronic myeloproliferative disorders (mpds), is associated with cerebral venous thrombosis (cvt) in the absence of mpd. |
| PubMedID- 24610470 | thrombosis in myeloproliferative neoplasms. |
| PubMedID- 21151606 | Hemoglobin of 13.8 g/dl or lower, white blood cells count of 7.8x10(9)/l or lower, and platelet count of 400x10(9)/l or lower (adjusted odds ratio = 4.43, 95% ci = 1.45-13.49) thirteen patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls. |
| PubMedID- 22796622 | The occurrence of myocardial infarction in myeloproliferative disease is mostly attributed to coronary thrombosis due to hyperviscosity and thrombocytosis. |
| PubMedID- 22826442 | thrombosis in myeloproliferative neoplasms with jak2v617f mutation. |
| PubMedID- 23820940 | In spite of their recognized risk of thrombosis, patients with myeloproliferative neoplasms (mpn) show little or no abnormalities of traditional coagulation tests, perhaps because these are unable to represent the balance between pro- and anticoagulants nor the effect of platelets and blood cells. |
| PubMedID- 25042466 | Cerebral vein thrombosis in patients with philadelphia-negative myeloproliferative neoplasms. |
| PubMedID- 21282719 | Pathophysiology of thrombosis in myeloproliferative neoplasms. |
| PubMedID- 25840747 | We examined a consecutive series of 29 patients with myeloproliferative neoplasms (mpns) associated with splanchnic vein thrombosis (svt) in order to evaluate their bone marrow morphology and identify possible associations between histological findings and clinical features. |
| PubMedID- 20052751 | Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. |
Page: 1